Matisse Pharmaceuticals

Year of investment: 2016

Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.

See www.Matisse-Pharma.com